JP2006524190A - 薬剤のメントール溶液 - Google Patents
薬剤のメントール溶液 Download PDFInfo
- Publication number
- JP2006524190A JP2006524190A JP2006501172A JP2006501172A JP2006524190A JP 2006524190 A JP2006524190 A JP 2006524190A JP 2006501172 A JP2006501172 A JP 2006501172A JP 2006501172 A JP2006501172 A JP 2006501172A JP 2006524190 A JP2006524190 A JP 2006524190A
- Authority
- JP
- Japan
- Prior art keywords
- drug
- drugs
- menthol
- bioavailability
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/401—Proline; Derivatives thereof, e.g. captopril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Transplantation (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US44924603P | 2003-02-20 | 2003-02-20 | |
| PCT/US2004/004684 WO2004073686A2 (en) | 2003-02-20 | 2004-02-17 | Menthol solutions of drugs |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2006524190A true JP2006524190A (ja) | 2006-10-26 |
| JP2006524190A5 JP2006524190A5 (enExample) | 2009-12-10 |
Family
ID=32908699
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006501172A Pending JP2006524190A (ja) | 2003-02-20 | 2004-02-17 | 薬剤のメントール溶液 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20040198646A1 (enExample) |
| EP (1) | EP1596832A2 (enExample) |
| JP (1) | JP2006524190A (enExample) |
| KR (1) | KR20050116368A (enExample) |
| CN (1) | CN1882313A (enExample) |
| AU (1) | AU2004212989A1 (enExample) |
| CA (1) | CA2516798A1 (enExample) |
| EA (1) | EA200501301A1 (enExample) |
| MX (1) | MXPA05008902A (enExample) |
| WO (1) | WO2004073686A2 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2007508249A (ja) * | 2003-10-10 | 2007-04-05 | ライフサイクル ファーマ アクティーゼルスカブ | フィブラートとスタチンを含む固体剤型 |
| US9173847B2 (en) | 2003-10-10 | 2015-11-03 | Veloxis Pharmaceuticals A/S | Tablet comprising a fibrate |
| JP5069001B2 (ja) | 2003-10-10 | 2012-11-07 | ベロクシス ファーマシューティカルズ エー/エス | フィブラートを含む固体投与形態 |
| US20070166360A1 (en) * | 2004-03-31 | 2007-07-19 | Kowa Co., Ltd. | External preparation |
| EP1720523A2 (en) * | 2004-08-13 | 2006-11-15 | Teva Pharmaceutical Industries Ltd | Cyclosporin formulations |
| EA200701750A1 (ru) * | 2005-03-30 | 2008-02-28 | Тева Фармасьютикал Индастриес Лтд. | Улучшенные составы фенофибрата, содержащие ментол или пэг/полоксамер |
| EP1707197A1 (en) | 2005-03-30 | 2006-10-04 | Teva Pharmaceutical Industries Ltd. | Formulations containing fenofibrate and a surfactant mixture |
| JP2008534586A (ja) * | 2005-03-30 | 2008-08-28 | テバ ファーマシューティカル インダストリーズ リミティド | フェノフィブレートの改良された製剤 |
| EP1898922A4 (en) * | 2005-07-04 | 2012-03-14 | Ramu Krishnan | MEDICINE OR IMPROVED PHARMACEUTICAL COMPOUNDS AND PREPARATION THEREOF |
| US20070015834A1 (en) * | 2005-07-18 | 2007-01-18 | Moshe Flashner-Barak | Formulations of fenofibrate containing PEG/Poloxamer |
| US20070015833A1 (en) * | 2005-07-18 | 2007-01-18 | Moshe Flashner-Barak | Formulations of fenofibrate containing menthol |
| US20240041974A1 (en) * | 2019-09-09 | 2024-02-08 | Taejoon Pharmaceutical Co., Ltd. | Nanoemulsion ophthalmic composition comprising cyclosporine and menthol, and preparation method thereof |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH11507356A (ja) * | 1995-06-07 | 1999-06-29 | アブマックス,インコーポレイティド | 経口薬理化合物の生物有用性を高めるためのエッセンシャルオイルの利用 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6331318B1 (en) * | 1994-09-30 | 2001-12-18 | Emisphere Technologies Inc. | Carbon-substituted diketopiperazine delivery systems |
| US5567592A (en) * | 1994-02-02 | 1996-10-22 | Regents Of The University Of California | Screening method for the identification of bioenhancers through the inhibition of P-glycoprotein transport in the gut of a mammal |
| US5665386A (en) * | 1995-06-07 | 1997-09-09 | Avmax, Inc. | Use of essential oils to increase bioavailability of oral pharmaceutical compounds |
| US5716928A (en) * | 1995-06-07 | 1998-02-10 | Avmax, Inc. | Use of essential oils to increase bioavailability of oral pharmaceutical compounds |
| US5968972A (en) * | 1995-10-26 | 1999-10-19 | Baker Norton Pharmaceuticals, Inc. | Method for increasing the oral bioactivity of pharmaceutical agents |
| ATE288255T1 (de) * | 1996-04-12 | 2005-02-15 | Novadel Pharma Inc | Polares bukkales spray |
| US20010049363A1 (en) * | 1998-05-08 | 2001-12-06 | Warner-Lambert Company | Oral composition containing NSAIDs and essential oils |
| US6878693B2 (en) * | 2001-09-28 | 2005-04-12 | Solubest Ltd. | Hydrophilic complexes of lipophilic materials and an apparatus and method for their production |
| KR20040098023A (ko) * | 2002-03-26 | 2004-11-18 | 테바 파마슈티컬 인더스트리즈 리미티드 | 약물 미세입자 |
-
2004
- 2004-02-17 MX MXPA05008902A patent/MXPA05008902A/es unknown
- 2004-02-17 WO PCT/US2004/004684 patent/WO2004073686A2/en not_active Ceased
- 2004-02-17 CN CNA2004800101740A patent/CN1882313A/zh active Pending
- 2004-02-17 KR KR1020057015441A patent/KR20050116368A/ko not_active Ceased
- 2004-02-17 EP EP04711866A patent/EP1596832A2/en not_active Withdrawn
- 2004-02-17 AU AU2004212989A patent/AU2004212989A1/en not_active Abandoned
- 2004-02-17 CA CA002516798A patent/CA2516798A1/en not_active Abandoned
- 2004-02-17 US US10/781,543 patent/US20040198646A1/en not_active Abandoned
- 2004-02-17 EA EA200501301A patent/EA200501301A1/ru unknown
- 2004-02-17 JP JP2006501172A patent/JP2006524190A/ja active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH11507356A (ja) * | 1995-06-07 | 1999-06-29 | アブマックス,インコーポレイティド | 経口薬理化合物の生物有用性を高めるためのエッセンシャルオイルの利用 |
Non-Patent Citations (1)
| Title |
|---|
| JPN6009031595, 医療薬日本医薬品集, 19991025, p. 1422 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CA2516798A1 (en) | 2004-09-02 |
| CN1882313A (zh) | 2006-12-20 |
| KR20050116368A (ko) | 2005-12-12 |
| WO2004073686A3 (en) | 2004-11-04 |
| MXPA05008902A (es) | 2005-10-05 |
| US20040198646A1 (en) | 2004-10-07 |
| AU2004212989A1 (en) | 2004-09-02 |
| EA200501301A1 (ru) | 2006-04-28 |
| EP1596832A2 (en) | 2005-11-23 |
| WO2004073686A2 (en) | 2004-09-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2762013C (en) | Granulation of pirfenidone and pharmaceutically acceptable excipients | |
| BRPI0212922B1 (pt) | Composição farmacêutica na forma de um comprimido dispersável compreendendo uma dispersão sólida de 40-o-(2-hidroxietil)-rapamicina, seu processo de preparação e uso da dita composição | |
| JP2006524190A (ja) | 薬剤のメントール溶液 | |
| JPH10259131A (ja) | 経口投与用ラパマイシン処方 | |
| TW201521786A (zh) | 胺碘酮類似物(budiodarone)調配物 | |
| JP2006524190A5 (enExample) | ||
| KR20090086686A (ko) | 용출율이 개선된 실리마린 함유 약학적 조성물 및 이의제조방법 | |
| US20060141028A1 (en) | Cyclosporin formulations | |
| US20130143848A1 (en) | Use of megestrol acetate for improving heart function and the treatment of heart insufficiency | |
| EP1465607B1 (fr) | Compositions pharmaceutiques a liberation modifiee | |
| CN109496152A (zh) | 癸氧喹酯组合物的肌肉内库存及其预防和治疗的方法 | |
| JP7432501B2 (ja) | チモキノン含有組成物の調製法 | |
| US20080161404A1 (en) | Bicalutamide for Delivering Increasing Steady State Plasma Levels | |
| AU2008200464A1 (en) | Menthol solutions of drugs | |
| JP2688266B2 (ja) | アルドース還元酵素阻害作用を有し且つ吸収性の良好な薬剤組成物 | |
| AU2013201986A1 (en) | Capsule Formulation Of Pirfenidone And Pharmaceutically Acceptable Excipients | |
| AU2014240300C1 (en) | Capsule Formulation of Pirfenidone and Pharmaceutically Acceptable Excipients | |
| CN103142596A (zh) | 一种含替米沙坦和匹伐他汀的药物组合物 | |
| HK1168758A (en) | Capsule formulation of pirfenidone and pharmaceutically acceptable excipients | |
| HK1117762B (en) | Capsule formulation of pirfenidone and pharmaceutically acceptable excipients |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20090630 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20090929 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20091006 |
|
| A524 | Written submission of copy of amendment under article 19 pct |
Free format text: JAPANESE INTERMEDIATE CODE: A524 Effective date: 20091023 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20100928 |